| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Lin,Han-Fei | Chairman | 2.61% | |
| Li,Shi-Ren | Director | 1.50% | |
| Zhang,Zhi-Cheng | Director | 22.99% | ZHONG HUA SHI JI INVESTMENT CO., LTD. |
| Zhang,Zi-Cheng | Director | 22.99% | ZHONG HUA SHI JI INVESTMENT CO., LTD. |
| James Aiping Lee | Director | 3.08% | Bayberry Management LLC |
| Zhang,Zhen-Zhong | Director | 0.63% | |
| Liao,Ji-Zhou | Independent Director | 0.06% | |
| Ge,Zhi-Gang | Independent Director | 0.01% | |
| Chen,Zhao-Rong | Independent Director | 0.00% | |
| Lin,Yu-Ya | Independent Director | 0.00% |
Change Company Name to EASYWELL BIOMEDICALS, INC.
2024/03/11
Change Company Name to YIWEI BIOMEDICAL TECHNOLOGY CO., LTD. (FORMER NAME: HONGDIAN MEDICAL TECHNOLOGY CO., LTD.)
2022/08/24
Change Capital to 2,500,000,000
2022/07/06
Change Capital to 2,000,000,000
2019/07/12
Change Person in Charge to Lin,Han-Fei
2018/11/27
Change Capital to 1,500,000,000
2017/06/12
Change Company Name to EASYWELL BIOMEDICALS, INC.
2015/07/06
Change Capital to 800,000,000
2014/09/01
Change Person in Charge to Li,Shi-Ren
2013/11/11
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 151,543 | 540,438 | 271,628 |
| Operating cost | 67,943 | 241,040 | 100,910 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 83,600 | 299,398 | 170,718 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 83,600 | 299,398 | 170,718 |
| Operating expenses | 88,945 | 374,190 | 333,456 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -5,345 | -74,792 | -162,738 |
| Non-operating income and expenses | 4,445 | -13,495 | -7,171 |
| Net profit (loss) before tax | -900 | -88,287 | -169,909 |
| Income tax expense (benefits) | 233 | 157 | 256 |
| Net profit (loss) of ongoing business for the current period | -1,133 | -88,444 | -170,165 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -1,133 | -88,444 | -170,165 |
| Other comprehensive profit (loss), net | 5,110 | 20,264 | -8,960 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 3,977 | -68,180 | -179,125 |
| Net profit (loss) attributable to owners of parent company | -621 | -97,468 | -144,818 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -512 | 9,024 | -25,347 |
| Comprehensive profit (loss) attributable to owners of parent company | 4,419 | -77,724 | -153,476 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -442 | 9,544 | -25,649 |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 44,092 | -159,042 | -151,448 |
| Net cash inflows (outflows) from investing activities | 40,471 | -47,662 | 87,463 |
| Net cash inflow (outflow) from financing activities | -23,092 | 263,058 | 177,843 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 2,816 | 6,405 | -9,977 |
| Increase (decrease) in cash and cash equivalents in the current period | 64,287 | 62,759 | 103,881 |
| Beginning balance of cash and cash equivalents | 325,665 | 262,906 | 159,025 |
| Ending balance of cash and cash equivalents | 389,952 | 325,665 | 262,906 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 764,291 | 818,196 | 507,635 |
| Non-current asset | 682,025 | 687,111 | 706,149 |
| Total asset | 1,446,316 | 1,505,307 | 1,213,784 |
| Current liability | 356,188 | 423,706 | 127,567 |
| Non-current liability | 345,463 | 342,464 | 462,421 |
| Total liability | 701,651 | 766,170 | 589,988 |
| share capital | 1,246,895 | 1,217,908 | 1,158,658 |
| Equity - secruity token | - | - | - |
| capital reserve | 273,162 | 132,979 | 35,400 |
| retained earning | -811,381 | -654,349 | -570,156 |
| Other equity | 28,130 | 22,072 | -11,089 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 736,806 | 718,610 | 612,813 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 7,859 | 20,527 | 10,983 |
| Total Equity | 744,665 | 739,137 | 623,796 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 5 | 5 | 5 |
